MedPath

Guizhou Bailing Group Pharmaceutical Co.,Ltd.

Guizhou Bailing Group Pharmaceutical Co.,Ltd. logo
🇨🇳China
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

5

Active:1
Completed:3

Trial Phases

3 Phases

Phase 1:1
Phase 2:2
Phase 4:2

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials

Phase 2
2 (40.0%)
Phase 4
2 (40.0%)
Phase 1
1 (20.0%)

Kesuting Syrup in the Treatment of Corona Virus Disease 2019 (COVID-19)

Phase 4
Completed
Conditions
COVID-19 Pneumonia
Cough
Interventions
Drug: LianHuaQingWen Granules
Drug: Kesuting syrup
First Posted Date
2022-05-09
Last Posted Date
2022-09-19
Lead Sponsor
Guizhou Bailing Group Pharmaceutical Co Ltd
Target Recruit Count
200
Registration Number
NCT05366231
Locations
🇨🇳

Shanghai Public Health Clinical Center, Shanghai, Shanghai, China

Tangningtongluo Tablet in the Treatment of Non-proliferative Diabetic Retinopathy

Phase 2
Active, not recruiting
Conditions
Type2 Diabetes
Diabetic Retinopathy
Interventions
Drug: Tangningtongluo tablets
First Posted Date
2021-08-16
Last Posted Date
2023-05-09
Lead Sponsor
Guizhou Bailing Group Pharmaceutical Co Ltd
Target Recruit Count
240
Registration Number
NCT05007262
Locations
🇨🇳

Chongqing hospital of traditional Chinese Medicine, Chongqing, Chongqing, China

🇨🇳

Gansu Provincial Hospital of traditional Chinese Medicine, Lanzhou, Gansu, China

🇨🇳

People's Hospital of Anshun City Guizhou Province, Anshun, Guizhou, China

and more 10 locations

Multi-center Clinical Study of Guli Capsules in the Treatment of Knee Osteoarthritis

Phase 4
Conditions
Knee Osteoarthritis
Interventions
Drug: Guli capsule
Drug: Kangguzengsheng capsule
First Posted Date
2015-06-29
Last Posted Date
2015-06-29
Lead Sponsor
Guizhou Bailing Group Pharmaceutical Co Ltd
Target Recruit Count
220
Registration Number
NCT02484508
Locations
🇨🇳

Wangjing Hospital, Chinese Academy of Traditional Chinese Medicine, Beijing, Beijing, China

The Effect of Tang Ning Tongluo Formula in Type 2 Diabetics Clinical Analysis

Phase 2
Completed
Conditions
General Disorders and Administration Site Conditions
Interventions
Drug: Tangning Tongluo Capsule
First Posted Date
2014-06-25
Last Posted Date
2014-09-11
Lead Sponsor
Guizhou Bailing Group Pharmaceutical Co Ltd
Target Recruit Count
120
Registration Number
NCT02174042
Locations
🇨🇳

Nanmeng Tianyuan hospital; Dongfang Hospital; China-Japanese Friendship Hospital, Beijing Shi, Guizhou, China

Clinical Trials for the Optimal Dosage of Tang Ning Tongluo Capsule

Phase 1
Completed
Conditions
Accidental Exposure While Preparing Drug for Administration
Interventions
Drug: TNTL capsule
Drug: Placebo
First Posted Date
2014-06-11
Last Posted Date
2014-09-11
Lead Sponsor
Guizhou Bailing Group Pharmaceutical Co Ltd
Target Recruit Count
110
Registration Number
NCT02161276
Locations
🇨🇳

Tianyuan Hospital of Guiyang City, Guiyang, Guizhou, China

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.